Trial Profile
The lipid lowering effect of anagliptin in type 2 diabetes mellitus with dyslipidemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2015
Price :
$35
*
At a glance
- Drugs Anagliptin (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- 14 Apr 2015 Status changed from not yet recruiting to discontinued as per University Hospital Medical Information Network - Japan.
- 22 Apr 2014 New trial record